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Edited by Veli-Pekka LehtoAbstract In deletion mutant analyses of potential phosphoryla-
tion sites in RLIP76, we identiﬁed T297 and S509 as targets for
phosphorylation by PKCa. Phosphorylation at T297 increased
doxorubicin (DOX)-transport activity 2-fold for RLIP76 puri-
ﬁed from recombinant source, or from three small (H69, H1417,
H1618) and three non-small cell, one each derived from H226
(squamous), H358 (bronchio alveolar), and H1395 (adenocarci-
noma) lung cancer cell lines. T297 phosphorylation conferred sen-
sitivity to tryptic digestion at R293. The speciﬁc activity for
DOX-transport by RLIP76 puriﬁed from non-small cell, which
was primarily in the phosphorylated form, was approximately
twice that in small cell lung cancer cell lines. These ﬁnding oﬀer
a novel explanation for the observed intrinsic diﬀerences in sen-
sitivity to DOX between non-small cell and small cell lung cancer
cell lines.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
Keywords: PKCa; Doxorubicin; Drug-resistance; RLIP76;
SCLC; NSCLC1. Introduction
Doxorubicin (DOX) is a highly eﬀective anthracycline che-
motherapeutic agent belonging to the natural products class
of antineoplastic agents. It is a highly active agent in the che-
motherapeutic treatment of a number of human malignancies
including breast cancer, bladder cancer, multiple myeloma,
lymphoma, and small cell lung cancer [1–5]. In contrast to
its high activity in small cell lung cancer (SCLC), it is relatively
ineﬀective in non-small cell lung cancer (NSCLC), which rep-
resents about 4/5 of all lung cancers [6]. Even in SCLC,
acquired resistance to DOX is common, accounting for the fre-
quent failure to cure SCLC with DOX-based chemotherapyAbbreviations: RLIP76 (RALBP1), Ral-interacting protein; DOX,
doxorubicin; SCLC, small cell lung cancer; NSCLC, non-small cell
lung cancer; GSH, glutathione; GS-E, glutathione–electrophile conju-
gate; MRP, multi-drug resistance associated protein; PKC, protein-
kinase-C
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DOX-resistance of NSCLC and acquired DOX-resistance in
SCLC have been the subject of numerous investigations [7,8].
The inherently lower cellular accumulation of DOX in NSCLC
as compared with SCLC has been frequently attributed as a
major cause of DOX-resistance in NSCLC; increased pro-
tein-kinase-C (PKC) activity is also closely linked with
DOX-accumulation defective resistance. The mechanism
through which PKC can inﬂuence cellular DOX-accumulation
remains unclear since regulation of ABC-transporter activity
by PKC has not been established. PKCa has been shown to
phosphorylate and stimulate the activity of RLIP76 [9,10], a
novel non-ABC transporter of DOX [11,12].
RLIP76 is a multifunctional modular protein, which was ini-
tially cloned as a Ral binding protein and predicted to be a
Ral-eﬀector [13–16]. We cloned RLIP76 independently in
search of ATPases capable of and being stimulated by glutathi-
one–electrophile conjugates (GS-E), and have demonstrated
that its is a stress-responsive protein capable of providing pro-
tection to cells from a variety of oxidative stressors including
heat, UV-irradiation, X-irradiation, and oxidant chemicals
[17–20]; these stressors are all known to cause formation of
increased electrophilic lipid peroxidation byproducts which
are metabolized to GS-E. GS-E are potent inhibitors of en-
zymes involved in glutathione (GSH)-linked oxidative stress
defense, and our studies clearly show that the transport activ-
ity of RLIP76 is important for the protective function of
RLIP76. Recent studies by other investigators, showing that
RLIP76 is a regulator of the Rho/Rac subfamily of G-proteins,
known regulators of xenobiotic metabolism and resistance
[21,22], combined with our studies showing that RLIP76 is a
multispeciﬁc transporter, suggest that RLIP76 protects cells
from apoptosis caused by drug/toxin/oxidant stresses by pre-
venting cellular accumulation of toxic-drugs and GSH-conju-
gates of endogenous and exogenous electrophilic toxins
through its transport activity [11,12,23–25].
Multiple potential mechanisms for DOX-eﬄux have been
identiﬁed in lung cancer cells, primarily belonging to the
ABC-transporter super-family, though rigorous evidence for
DOX-transport activity in isolated systems is lacking for most.
P-glycoprotein (mdr-1 gene product, Pgp) is the prototypical
and best characterized membrane protein which has been
shown to mediate the ATP-dependent transmembrane trans-
port of DOX, as is a major cause of a DOX-accumulation
defective phenotype in many types of human cancers, but itsation of European Biochemical Societies.
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ited because of it relatively low expression in lung cancer cells
[23–26]. Other ABC-super family transporters such as the
MRP1 (ABCC2, multidrug-resistance associated protein) and
BCRP (ABCG2) are more signiﬁcant determinants of DOX-
transport in lung cancer cells [27]. However, our recent studies
in panels of SCLC and NSCLC have shown that RLIP76 con-
tributes approximately 2/3 of total DOX-transport activity
with the remainder being contributed to by ABC-transporter
[23]. Similarly, RLIP76 was also found to be the predominant
GS-E transporter of the model substrate LTC4 in cancer cells
[28]. Greater than 80% loss in liver and heart tissue of total
DOX and GS-E transport activity in RLIP76 knockout mice
[29] strongly supports the hypothesis that RLIP76 can contrib-
ute substantially to total DOX-transport capacity in cancer
cells. Sequence analysis of RLIP76 indicates the presence of
four potential PKCa phosphorylation sites [11]. Since
increased PKC activity is correlated with increased DOX-resis-
tance and decreased cellular DOX-accumulation, and because
RLIP76 can be activated through phosphorylation by PKC
[9,10], the present studies were carried out to test the hypoth-
esis that cellular RLIP76 levels and transport activity, and the
regulation of RLIP76 by PKCa is a signiﬁcant determinant of
inherent and acquired DOX-resistance in lung cancer.2. Materials and methods
2.1. Materials
Sources for reagents for tissue culture, protein puriﬁcation, and
transport studies were the same as previously reported [30–34].
[c-32P] ATP (3000 Ci/mmol) was purchased from Pharmacia Biotech
(Piscataway, NJ). [14C] DOX (speciﬁc activity 57 mCi/mmol) was pur-
chased from Amersham Corporation (Arlington Heights, IL). Source
of anti-RLIP76 IgG used in these studies were the same as previously
described [25]. PKCa was obtained from Molecular Probes, Oregon.
2.2. Cell lines and cultures
Human SCLC line (H69, H1417, H1618) and NSCLC lines (H226,
squamous cell carcinoma; H358, bronchio alveolar; H1395, adenocar-
cinoma) were studied. All cells were cultured at 37 C in a humidiﬁed
atmosphere of 5% CO2 in RPMI-1640 medium supplemented with 10%
(v/v) heat-inactivated FBS, 1% (v/v) P/S solution, 2 mM L-glutamine,
10 mM HEPES, 1 mM sodium pyruvate, 4.5 g/L glucose, and 1.5 g/L
sodium bicarbonate.2.3. Functional reconstitution of DOX-transport activity of RLIP76 in
artiﬁcial liposomes
We have previously shown functional reconstitution of DOX-trans-
port by puriﬁed and authenticated RLIP76 [17,30], using methods
pioneered by others for reconstitution of the transport activity of
H+-ATPase [35,36]. RLIP76 protein was puriﬁed from SCLC (H69,
H1417, H1618), NSCLC (H226, H358, H1395) and from Escherichia
coli BL21(DE3) expressing either wild-type or deletion mutant
RLIP76. Puriﬁcation was monitored by measurements of ATPase
activity [25], and purity was conﬁrmed by SDS–PAGE, Western blot,
and amino acid composition analysis as previously described [17]. Puri-
ﬁed protein was dialyzed against liposome reconstitution buﬀer
(10 mM Tris–HCl, pH 7.4, 2 mM MgCl2, 1 mM EGTA, 100 mM
KCl, 40 mM sucrose, 2.8 mM b-mercaptoethanol, 0.05 mM BHT,
and 0.025% polidocanol). An aqueous emulsion of soybean asolectin
(40 mg/ml) and cholesterol (10 mg/ml) was prepared in the reconstitu-
tion buﬀer by sonication. This emulsion was diluted 10-fold by addi-
tion of dialyzed RLIP76 in reconstitution buﬀer to achieve a ﬁnal
RLIP76 concentration of 0.05 mg/ml. The reaction mixture was soni-
cated at 15 s at 50 W. Vesiculation was initiated by addition of SM-2
Bio-beads (200 mg/ml) pre-equilibrated in the reconstitution buﬀer(without polidocanol). Vesiculation was carried out for 4 h at 4 C, fol-
lowed by removal of SM-2 Bio-beads by centrifugation. The vesicles
were collected and analyzed for protein content, transport activity,
and microbial contamination. Control vesicles to measure non-speciﬁc
transport, were prepared using an equal amount of crude protein from
E. coli not expressing RLIP76.
2.4. DOX transport in RLIP76-liposomes
Transport studies of DOX in reconstituted vesicles were performed
by the method as described previously [17,23], using 250 ng protein
per 40 ll reaction mixture. Equimolar concentration of NaCl was
substituted for ATP in the controls. ATP-dependent uptake of 14-
[14C] DOX (speciﬁc activity 8.5 · 104 cpm/nmol) was determined by
subtracting the radioactivity (cpm) of the control without ATP from
that of the experimental containing ATP, and the transport of DOX
was calculated in terms of nmol/min/mg protein. Liposomes prepared
without addition of RLIP76 were used for controls.
2.5. Generation of deletion mutants
Deletion mutants were made by PCR-based site-directed mutagene-
sis as described previously [32]. Full length RLIP76 in pET30a(+)
expression vector was used as template, with upstream primer
5 0GGCGGATCCATGACTGAGTGCTTCCT (BamH1 restriction
site is underlined) and downstream primer 5 0CCGCTCGAGTAGAT-
GGACGTCTCCTTCCTATCCC (XhoI restriction site underlined).
The mutagenic primers used were 5 0CAAGAAGCCCAGCTT-
TAAGGAAAAGGAT3 0 (for RLIP76del-118–120), 5 0GTGGGAG-
GACCACGGAGGTGCAGGAATTCCA (for RLIP76del-297–299),
5 0GCCCAACTGTGCAGATCGTCCTGTATGTGT30 (for RLIP-
76del-353–355), and 5 0GTTCAATCTCTTCGGCAATCTGCCGGC-
GC3 0 (for RLIP76del-509–511) and respective and reverse complements.
In two separate reactions, the regions to be mutated were ampliﬁed by
PCR at the following incubation conditions: DNA template 500 ng,
primers 30 pmol each, dNTPs 2.5 lM, thermopol buﬀer 1X, BSA 1X
and Vent polymerase 2.5 U. PCR cycles were at 94 C for 5 min fol-
lowed by 30 cycles of 94 C for 30 s; 60 C for 30 s and 1 min at
72 C and a ﬁnal extension at 72 C for 7 min. The PCR products were
gel puriﬁed using Qiagen gel extraction kit and the puriﬁed products of
both PCR reactions in the molar ratio of 1:1 were extended at 94 C
for 5 min followed by 12 cycles of 94 C for 30 s; 50 C for 1 min
and at 72 C for 2 min and a ﬁnal extension at 72 C for 7 min. The
PCR products were puriﬁed by using Qiagen PCR puriﬁcation kit
and digested with BamHI/XhoI restriction enzymes.
The BamHI/XhoI cleaved PCR products were gel puriﬁed and
ligated into pET30a(+) previously digested with the same restriction
enzymes. The ligated products were cloned and the colonies were
screened for mutation and plasmid DNA was puriﬁed from the over-
night culture of single colony using Qiagen DNA puriﬁcation kit.
Techniques for restriction enzyme digestion, ligation, transformation
and other standard molecular biology manipulations were based on
methods described by Sambrook et al. [37]. The authenticity of the
mutation and the absence of other fortuitous mutations were con-
ﬁrmed by DNA sequencing.2.6. Phosphorylation of RLIP76 by PKCa
Commercially available puriﬁed PKCa (Molecular Probes Inc., Ore-
gon, USA) was incubated with puriﬁed RLIP76 isolated from either
cells or recombinant source (0.25 lg PKCa per 5 lg puriﬁed RLIP76),
0.1 mg phosphatidyl serine (from bovine brain), 20 lg sonicated 1-ole-
olyl-2-acetyl-[s,n]-glycerol, and 1 mM [c-32P] ATP (sp. act. 1 lCi/
mmol) for 30 min at 30 C. The protein was then subjected to SDS–
PAGE and the gel was visualized using phosphorimaging as previously
described [18].
2.7. Eﬀect of PKCa-mediated phosphorylation on RLIP76-mediated
DOX-transport
DOX-transport in RLIP76 liposomes was carried after pre-treat-
ment with PKCa as above except that non-radiolabeled ATP for
PKCa catalyzed phosphorylation of puriﬁed RLIP76. Because residual
ATP may interfere with the no-ATP control in the transport assay, and
we included controls in which RLIP76 was pre-incubated with ATP
alone (without PKCa), PKCa alone (without ATP), or without either
PKCa or ATP.
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For digestion with trypsin, PKCa was incubated with puriﬁed
RLIP76, isolated from either cells or recombinant source (0.5 lg
PKCa per 10 lg puriﬁed RLIP76), 0.1 mg phosphatidyl serine (from
bovine brain), 20 lg sonicated 1-oleolyl-2-acetyl-[s,n]-glycerol, and
1 mM ATP for 30 min at 30 C followed by incubation with trypsinFig. 1. Phosphorylation of bacterially expressed, puriﬁed rec-RLIP76 by PK
with PKCa (0.25 lg per 5 lg RLIP76 protein) for 30 min at 37 C along with [
using 12.5% acrylamide gels and radioactivity was visualized by phosphorima
PKC inhibitor bis-indolylmaleimide concentration was 10 nM. Exposure time
was quantiﬁed by scanning densitometry.
Fig. 2. Eﬀect of PKCa on DOX-transport by rec-RLIP76. ATP-dependent D
described [17]. The RLIP76-liposomes were divided into four groups for pre-in
and no PKCa, (3) no ATP and 0.05 lg PKCa/lg RLIP76, and 4 mM ATP a
then carried out in the usual manner by addition of proteoliposomes (conta
[14C] DOX (3.6 lM, speciﬁc activity 8.5 · 104 cpm/nmol) and either 0 or 4 mM
by subtracting uptake in the absence of ATP from that in the presence o
experiments, each in triplicate (n = 9). Results of these studies performed i
deletion mutants RLIP76del-118–120, RLIP76del-509–511, RLIP76del-297–299, andin 0.1 M ammonium bicarbonate, pH 7.8, for 4 h at 37 C at an en-
zyme substrate ratio of 1:25 (wt/wt). Proteolysis was terminated by
freezing and lyophilization, and resulting peptides were dissolved
in an appropriate volume of electrophoresis sample buﬀer, followed
by SDS–PAGE in 17.5% gel using the buﬀer system of Laemmli
[38].Ca. Puriﬁed RLIP76 (wild-type and deletion mutants) was incubated
c-32P] ATP (sp. act. 1 lCi/mmol). Protein was subjected to SDS–PAGE
ger. Reaction mixtures applied to each lane are indicated in the ﬁgure.
of autoradiograph was 48 h. Fold increase of RLIP76 phosphorylation
OX transport was measured in RLIP76 proteoliposomes as previously
cubation for 30 min at 37 C: (1) no ATP and no PKC, (2) 1 mM ATP
nd 0.05 lg PKCa/lg RLIP76, as indicated in the ﬁgure. Transport was
ining 250 ng RLIP76 per ﬁltration well) to transport buﬀer containing
ATP. ATP-dependent transport presented in the ﬁgure was calculated
f 4 mM ATP. Results are average and standard deviations from 3
n proteoliposomes reconstituted with either wild-type RLIP76 or the
RLIP76del-353–355.
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3.1. Identiﬁcation of PKCa phosphorylation sites in RLIP76
Incubation of puriﬁed recombinant RLIP76 with [c-32P]
ATP in the absence of PKCa (control) showed labeling
(Fig. 1) consistent with known ATP-binding at two sites [18].
Incubation in the presence of PKCa resulted in signiﬁcantly
increased radioactive labeling, which was nearly completely
inhibited by the PKCa-inhibitor, bis-indolylmaleimide, indi-
cating PKCa-mediated phosphorylation. These ﬁndings are
consistent with our previous ﬁndings [28]. Our amino acid
sequence analysis of RLIP76 has indicated presence of four
potential sites for PKCa-mediated phosphorylation, S118,
T297, S353 and S509 [11]. Mutants were constructed in which
these sequences were deleted, and deletion-mutants as well as
the wild-type protein were puriﬁed and [c-32P] ATP labeling
was carried out. PKCa-mediated increase in radiolabeling of
RLIP76 was diminished in the deletion mutants. The most
marked eﬀect was found with RLIP76del-297–299 (T297), and pro-
gressively less with RLIP76del-509–511 (S509), RLIP76del-353–355
(S353), and RLIP76del-118–120 (S118). These ﬁndings indicated
that PKCa functions to phosphorylate RLIP76, with phos-
phorylation eﬃciency for T297 > S509 > S353 > S118.Fig. 3. Eﬀect of PKCa-mediated phosphorylation on DOX-transport by R
studies performed with RLIP76 puriﬁed from SCLC (H69, H1417 and H161
given in the legend for Fig. 2. Insets. Phosphorylation of corresponding reac
indicated for Fig. 1.3.2. The eﬀect of PKCa-mediated phosphorylation of
recombinant RLIP76 on DOX-transport
ATP-dependent transport of DOX for each of these mutants
was examined in puriﬁed fractions of wild-type or deletion-
mutant RLIP76 reconstituted in artiﬁcial proteoliposomes.
The proteoliposomes thus prepared were divided into four
pre-treatment groups: without or with 1 mM ATP and without
or with 12.5 ng PKCa. After pre-treatment for 30 min, DOX-
transport was measured by incubating these proteoliposomes
without or with 4 mM ATP and transport studies were carried
out as described above. Results of these studies (Fig. 2) showed
that pre-incubation with PKCa in the presence of ATP re-
sulted in a signiﬁcant increase in transport activity (1.76-fold
activation) of wild-type RLIP76. This increase in transport
activity caused by pre-incubating with ATP and PKCa was
slightly less (1.65-fold activation) for RLIP76del-118–120, but
this was not statistically signiﬁcant. A statistically signiﬁcant
blunting (P < 0.05) of the PKCa eﬀect was observed with
RLIP76del-509–511 (1.51-fold activation); a more marked eﬀect
was seen with RLIP76del-297–299 (only 1.15-fold activation).
The fourth mutant (RLIP76del-353–355) had no signiﬁcant eﬀect.
It should be noted that transport activity in the absence of
PKCa was not diﬀerent for the four mutants as compared withLIP76 puriﬁed from a panel of SCLC and NSCLC. DOX-transport
8) and NSCLC (H226, H358 and H1395) is also presented. Details are
tion mixture was analyzed by phosphorimaging of SDS–PAGE gels as
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incubation with PKCa caused not detectable increase in trans-
port activity, conﬁrming that the observed eﬀect was not a
non-speciﬁc eﬀect of the presence of PKCa. With ATP
included in the pre-incubation medium in the absence of
PKCa, a slight increase in activity was evident, either due to
non-enzymatic phosphorylation, or due to the presence of
greater than 4 mM ATP (due to residual ATP from the pre-
incubation mixture) during transport studies. These studies
clearly indicate that PKCa can activate RLIP76, and that
the majority of this eﬀect is abrogated by deletion of T297.
3.3. The eﬀect of PKCa-mediated phosphorylation of lung
cancer RLIP76 on DOX-transport
Eﬀect of PKCa-mediated phosphorylation on DOX-trans-
port by lung cancer RLIP76 was examined using puriﬁed
RLIP76 from three SCLC (H69, H1417, H1618) and three
NSCLC (H226, H358, H1395) (Fig. 3). In the absence of
PKCa, DOX-transport by RLIP76 from NSCLC was signiﬁ-
cantly greater than in SCLC, consistent with our previous
studies with a panel of six NSCLC and six SCLC cell lines
[23–25]. As was the case for recombinant RLIP76, DOX-trans-
port activity of protein puriﬁed from each of SCLC or NSCLCFig. 4. Partial tryptic digestion of RLIP76 puriﬁed from recombinant sour
RLIP76 from recombinant source and SCLC (H69, H1417 and H1618) and N
silver-stained SDS–PAGE of RLIP76 without (upper panel) or with limited t
arrow in lower panel points at a peptide band at Mr 44 kDa with N-termicell lines was increased approximately 70% when pre-incu-
bated with PKCa and ATP. That this increased activity was
due to PKCa-mediated phosphorylation was conﬁrmed by
SDS–PAGE and autoradiography (see Fig. 3, insets). These
ﬁndings indicate that RLIP76 from SCLC and NSCLC can
be phosphorylated by PKCa, and that this phosphorylation
results in increased transport activity of RLIP76 from both
SCLC and NSCLC.
3.4. Eﬀect of PKCa-mediated phosphorylation on sensitivity to
limited tryptic digestion
In previous studies [25], we have found that both SCLC and
NSCLC cell lines contain similar amounts of RLIP76 protein
(0.53 ± 0.04% of total membrane protein, n = 12), but the spe-
ciﬁc activity of RLIP76 from NSCLC was 2-fold greater than
from SCLC, both in ATPase activity and transport activity.
Post-translational modiﬁcations were suggested in previous
studies by slight diﬀerences in Mr (slightly greater for RLIP76
from NSCLC), as well as diﬀerences in susceptibility to limited
tryptic digestion. These studies showed the presence of a
44 kDa peptide resulting from limited proteolytic digestion
of RLIP76 from NSCLC, which was absent from SCLC.
The N-terminal sequence of this 44 kDa peptide revealed thece and SCLC and NSCLC cells. Proteolytic susceptibility of puriﬁed
SCLC (H226, H358 and H1395) cell lines were analyzed by comparing
ryptic digestion (lower panel) carried out as described in Section 2. The
nal sequence 294TTETE.
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the possibility that diﬀerential phosphorylation at T297 could
be responsible for the diﬀerential proteolytic susceptibility to
trypsin. In present studies, we tested this postulate by compar-
ing silver-stained SDS–PAGE of recombinant, three SCLC,
and three NSCLC RLIP76 proteins without or with pre-treat-
ment with PKCa (Fig. 4). Whereas puriﬁed recombinant
RLIP76 revealed no band at 44 kDa, pre-treatment with
PKCa resulted in appearance of the 44 kDa band. This band
was also lacking in RLIP76 puriﬁed from all SCLC, as well
as in recRLIP76 del-297–299, but was present in the protein puri-
ﬁed from all NSCLC without or with PKCa pre-treatment.
Pre-treatment of the protein from SCLC with PKCa caused
the appearance of this band. The 44 kDa band was not seen
upon PKCa pre-treatment of recRLIP76-del297–299. These
ﬁndings indicate that in NSCLC, RLIP76 exists predominantly
as the phosphorylated form at T297, which confers a signiﬁ-
cantly greater DOX-transport activity, as well as characteristic
susceptibility to serine protease at T294.4. Discussion
Diﬀerential expression or activity of PKC has been shown in
several studies to be a primary determinant of the inherent
DOX resistance of NSCLC as compared with SCLC [39,40].
Increased PKCa activity has also been shown to confer
decreased DOX-accumulation in NSCLC as compared with
SCLC. However, decreased DOX-accumulation in NSCLC
has not been explained previously by any known direct eﬀects
of PKC on identiﬁed transporters shown to transport DOX by
reconstitution in proteoliposomes. Among these transporters,
P-glycoprotein (Pgp) is known to be phosphorylated by PKCa,
but this does not have eﬀect of its DOX-transport activity
[41,42], and Pgp contributes relatively little to total DOX
transport activity in lung cancer cells [23]. PKCa has not been
shown to regulate the activity of other ABC-transporters. Pres-
ent ﬁndings, for the ﬁrst time, show phosphorylation and
upregulation of activity of a DOX-transporter, RLIP76.
Taken together with our ﬁnding in panels of several SCLC
and NSCLC cell lines showing a consistently 2-fold higher
activity of RLIP76 in NSCLC as compared with SCLC, pres-
ent ﬁndings suggest a novel molecular explanation for the
observed inherently greater DOX-resistance of NSCLC as
compared with SCLC. Our ﬁndings predict that inhibition of
PKCa and RLIP76 should result in synergistic increase in
DOX-sensitivity. These ﬁndings have signiﬁcant implica-
tions toward the understanding of the mechanisms of DOX-
resistance in lung cancer, and also towards design of therapy
regimens.
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